+1 (704) 266-3234
+1 (704) 266-3234You are here :
Published on: May 2022 | From USD $2900 | Published By: GLOBAL DATA | Number Of Pages: 53
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report 'Histone Deacetylase 4 - Drugs In Development, 2022'; Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes.
The report 'Histone Deacetylase 4 - Drugs In Development, 2022' outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology and Cardiovascular which include indications Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Myeloma (Kahler Disease), Mycosis Fungoides, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Pulmonary Arterial Hypertension, Rhabdomyosarcoma and Sezary Syndrome.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4SC AG
KYAN Therapeutics Inc
MEI Pharma Inc
Mirati Therapeutics Inc
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drug Profiles
Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
KYAN-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MC-1568 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mocetinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
pracinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
resminostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jul 03, 2020: Helsinn and MEI stop Phase III trial of pracinostat in AML
May 13, 2020: Helsinn and MEI Pharma announce updated clinical data from the phase 2 study evaluating pracinostat in combination with azacitidine in patients with high/very-high risk myelodysplastic syndromes
Feb 14, 2019: Helsinn and MEI Pharma announce publication of phase II data for Pracinostat in combination with Azacitidine in the frontline treatment of older AML patients unfit for intensive chemotherapy, in Blood Advance
Jan 28, 2019: 4SCâs pivotal RESMAIN study of resminostat in CTCL receives second positive safety review
Dec 03, 2018: Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Nov 20, 2018: 4SC reaches significant milestone with enrollment of 100 patients in pivotal RESMAIN study of resminostat as CTCL maintenance therapy
Nov 09, 2018: Mirati presents data from ongoing phase 2 clinical trial of Mocetinostat in combination with Durvalumab at the SITC 33rd Annual Meeting
Nov 05, 2018: Mirati to present new data from ongoing phase 2 clinical trial on mocetinostat and durvalumab at the SITC 33rd Annual Meeting
Nov 01, 2018: MEI Pharma to present data from Phase 2 trial of Pracinostat at ASH 2018
Jun 28, 2018: New data supports resminostatâs mechanism of action in CTCL maintenance therapy
May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients
May 30, 2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f
Apr 19, 2018: Phase II study of 4SCâs resminostat in biliary tract cancer in Japan is initiated
Apr 11, 2018: Yakult Honsha recruits first Japanese patient in 4SCâs pivotal RESMAIN study of resminostat in CTCL
Mar 27, 2018: Yakult Honsha joins 4SCâs pivotal RESMAIN study of resminostat in CTCL - 4SC receives milestone payment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 4SC AG, 2022
Pipeline by KYAN Therapeutics Inc, 2022
Pipeline by MEI Pharma Inc, 2022
Pipeline by Mirati Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
In-depth database
Our Report’s database covers almost all topics of all regions over the Globe..
Recognised publishing sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales support.
Safe & Secure
Complete secure payment process.
: sales@marketintelligencedata.com
: 1137 waynewood dr,Waxhaw NC 28173 ,United States
: +1 (704) 266-3234
